JMP Cuts Pharmasset (VRUS) to Market Perform
Tweet
Share
E-mailGet Alerts VRUS Hot Sheet
Price: $0.00 --0%
Rating Summary:
3 Buy, 10 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 2
Rating Summary:
3 Buy, 10 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 2
Join SI Premium – FREE
JMP Securities' Liisa Bayko just downgraded shares of Pharmasset (NASDAQ: VRUS) from Market Outperform to Market Perform in an intraday research note.
The stock is down more than 6 percent this afternoon following the addition of four new arms to its PSI-7977 Phase IIa trial.
For more ratings news on Pharmasset click here and for the rating history of Pharmasset click here.
The stock is down more than 6 percent this afternoon following the addition of four new arms to its PSI-7977 Phase IIa trial.
For more ratings news on Pharmasset click here and for the rating history of Pharmasset click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Downgrades Merck KGaA (MRK:GR) (MKGAF) to Hold
- ICICI Securities Downgrades Latent View Analytics (LATENTVI:IN) to Add (2)
- ICICI Securities Downgrades Wipro Ltd. (WPRO:IN) (WIT) to Reduce (4)
Create E-mail Alert Related Categories
DowngradesRelated Entities
JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
